The metabolic syndrome: An emerging health epidemic in women

Progress in Cardiovascular Diseases

Volumn 46, Issue 4, 2004, Pages 321-336

  Steinbaum, Suzanne R ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPOPROTEIN;

CALORIC RESTRICTION; CHOLESTEROL DIET; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC OBESITY; DIABETOGENESIS; EPIDEMIC; FEMALE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; REVIEW; RISK FACTOR;

EID: 1042287265     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2003.08.005     Document Type: Article

References (82)

1. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults Findings from the Third National Health and Nutrition Examination Survey . JAMA. 287:2002;356-359.
2. Goldstein B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol. 90:(suppl):2002;1G-10G.
3. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 289:2003;76-79.
4. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity. 2001;US Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD.
5. Mokdad A.H., Bowman B.A., Ford E.S., et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 286:2001;1195-1200.
6. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:2001;683-689.
7. Trevisan M., Liu J., Bahsas F.B., et al. Syndrome X and mortality a population based study . Am J Epidemiol. 148:1998;958-966.
8. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001;National Institutes of Health, Bethesda, MD. NIH Publication 01-3670.
9. Nathan D.M. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 347:2002;1342-1349.
10. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care. 16:(Suppl 2):1993;72-78.
11. Mak K.-H., Moliterno D.J., Granger C.B., et al. (GUSTO-1 Investigators) Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction . J Am Coll Cardiol. 30:1997;171-179.
12. O'Keefe J.H., Miles J.M., Harris W.H., et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 74:1999;171-180.
13. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:1996;952-957.
14. Meigs J.B., Mittleman M.A., Nathan D.M., et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis the Framingham Offspring Study . JAMA. 283:2000;221-228.
15. Lempiainen P., Mykkanen L., Pyorala K., et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 100:1999;123-128.
16. Thompson S.G., Kienast J., Pyke S.D., et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
17. Folsom A.R., Wu K.K., Rosamond W.D., et al. Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation. 96:1997;1102-1108.
18. Meade T.W., Brozovic M., Chakrabarti R.R., et al. Haemostatic function and ischaemic heart disease. Lancet. 2:1986;533-537.
19. Ridker P.M., Hennekens C.H., Stampfer M.J., et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 343:1994;940-943.
20. Pinkney J.H., Stehouwer C.D., Coppack S.W., et al. Endothelial dysfunction cause of the insulin resistance syndrome . Diabetes. 46:(Suppl 2):1997;S9-S13.
21. Meigs J.B., D'Agosino R.B. Sr, Wilson O.W., et al. Risk variable clustering in the insulin resistance syndrome the Framingham Offspring Study . Diabetes. 46:1997;1594-1600.
22. Garg R., Kumbkarni Y., Aljada A., et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 36:2000;430-435.
23. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy a reconcilable paradox . Circulation. 99:1999;2496-2498.
24. Ross R. Atherosclerosis an inflammatory disease . N Engl J Med. 340:1999;115-126.
25. Alessi M.C., Peiretti F., Morange P., et al. Production of plasminogen activator inhibitor 1 by human adipose tissue. Diabetes. 46:1997;860-867.
26. Calles-Escandon J., Mirza S.A., Sobel B.E., et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 47:1998;290-293.
27. Pickup J.C., Mattock M.B., Chusney G.D., et al. NIDDM as a disease of the immune system association of acute-phase reactants and interleukin-6 with metabolic syndrome X . Diabetologia. 40:1997;1286-1292.
28. Albert M.A., Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 286:2001;64-70.
29. Juhan-Vague, Alessi M.C., Vague P. Increased plasminogen activator inhibitor 1 levels. Diabetologia. 34:1991;457-462.
30. Dandona P., Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol. 90:(suppl):2002;27G-33G.
31. Steinberg H.O., Chaker H., Leaming R., et al. Obesity/insulin resistance is associated with endothelial dysfunction implications for the syndrome of insulin resistance . J Clin Invest. 97:1996;2601-2610.
32. Williams S.B., Cusco J.A., Roddy M.A., et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 27:1996;567-574.
33. Johnstone M.T., Creager S.J., Scales K.M., et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516.
34. Clarkson P., Celermajer D.S., Donald J.E. Impaired vascular reactivity in insulin dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 28:1996;573-579.
35. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities the role of insulin resistance and the sympathoadrenal system . N Engl J Med. 334:1996;374-381.
36. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM a balanced overview . Diabetes Care. 15:1992;318-368.
37. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation ed products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 318:1988;1315-1321.
38. Carey D.G., Jenkins A.B., Campbell L.V., et al. Abdominal fat and insulin resistance in normal and overweight women. Diabetes. 45:1996;633-638.
39. Zierath J.R., Livingston J.N., Thorne A., et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes relation to insulin receptor phosphorylation and intracellular signaling through the insulin receptor substrate-1 pathway . Diabetologia. 41:1998;1343-1354.
40. Cline G.W., Falk Peterson K., Krssak M., et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. New Engl J Med. 341:1999;240-246.
41. Reusch J. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 90:2002;19-26.
42. Marja P., Miettinen H., Laakso M., et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men the 22-year follow-up results of the Helsinki policemen study . Circulation. 98:1998;398-404.
43. Howard G., O'Leary D.H., Zaccaro D., et al. Insulin sensitivity and atherosclerosis. Circulation. 93:1996;1809-1817.
44. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 86:2000;943-949.
45. Sacks F.M. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease evidence from large-scale statin and fibrate trials . Am J Cardiol. 88:2001;14N-18N.
46. Laakso M., Sarlund H., Salonen R., et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 11:1991;1068-1076.
47. Young M.H., Jeng C.-Y., Sheu W.H.H., et al. Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary heart disease. Am J Cardiol. 72:1993;458-460.
48. Haffner S.M., Mykkanen L., Festa A., et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects implications for preventing coronary heart disease during the prediabetic state . Circulation. 101:2000;975-980.
49. Haffner S.M., Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 193:1997;152-162.
50. Salomaa V., Riley W., Kark J.D., et al. Arterial disease/hypertension/ angiotensin system: non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC study. Circulation. 91:1995;1432-1443.
51. Edwards K.L., Austin M.A., Newman B., et al. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb. 14:1994;1940-1945.
52. Folsom A.R., Szklo M., Stevens J., et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes the Atherosclerosis Risk in Communities (ARIC) Study . Diabetes Care. 20:1997;935-942.
53. Meigs J.B., D'Agostino R.B., Wilson P.W.F., et al. Risk variable clustering in the insulin resistance syndrome. Diabetes. 46:1997;1594-1600.
54. Garratt K.N., Brady P.A., Hassinger N.L., et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 33:1999;119-124.
55. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
56. Miyazaki Y., Mahankali A., Matsuda M., et al. Relationship between visceral fat and enhanced peripheral/hepatic insulin sensitivity after pioglitazone in type 2 diabetes. Diabetes. 50:(Suppl 2):2001;A126.
57. Arioglu E., Duncan-Morin J., Sebring N., et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 133:2000;263-274.
58. Ghanim H., Garg R., Alijada A., et al. Suppression of nuclear factor-kappa beta and stimulation of inhibitor kappa beta by troglitazone evidence for an anti-inflammatory effect and a potential antiathersclerotic effect in the obese . J Clin Endocrinol Metab. 86:2001;1306-1312.
59. Mayerson A.B., Hundal R.S., Dufour S., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
60. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
61. Mohanty P., Alijada A., Ghanim H., et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduced p47 subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1) evidence of a potent anti-inflammatory effect . Diabetes. 50:(Suppl 2):2001;A68.
62. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
63. Festa A., D'Agostino R. Jr, Howard G. Chronic subclinical inflammation as part of the insulin resistance syndrome The Insulin Resistance Atherosclerosis Study (IRAS) . Circulation. 102:2000;42-47.
64. Brunzell J., Cohen B., Kreider M., et al. Rosiglitazone favorable affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes. 50:(Suppl 2):2001;A141.
65. Raji A., Seely E.W., Bekins S.A., et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 26:2003;172-178.
66. Mather K.J., Verman S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 37:2001;1344-1350.
67. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 352:1998;854-865.
68. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403.
69. Wei M., Kampert J.B., Barlow C.E., et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight and obese men. JAMA. 282:1999;1547-1553.
70. Brandenburg S.L., Reusch J.E.D., Bauer T.A., et al. Effects of exercise training on oxygen uptake kinetic responses in women with type 2 diabetes. Diabetes Care. 22:1999;1640-1646.
71. Wallace M.B., Mills B.D., Browning C.L. Effects of cross-training on markers of insulin resistance/hyperinsulinemia. Med Sci Sports Exerc. 29:1997;1170-1175.
72. Knopp R.H., Walden C.E., Retzlaff B.M., et al. Long-term cholesterol-lowering effects of 4 fat restricted diets in hypercholesterolemic and combined hyperlipidemic men The Dietary Alternatives Study . JAMA. 278:1997;1509-1515.
73. Hu F.B., Stampfer M.J., Manson J.E., et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 337:1997;1491-1499.
74. Wadden T.A., Berkowitz R.I., Sarwer D.B., et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med. 161:2001;218-227.
75. Pyorala K., Pedersen T.R., Kjekshus J., et al. (Scandinavian Simvastatin Survival Study Group 4S): Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
76. Sacks F.M., Pfeffer M.A., Moye L.A., et al. (Cholesterol and Recurrent Events Trial Investigators) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . N Engl J Med. 335:1996;1001-1009.
77. Tenkanen L., Manttari M., Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil experience from the Helsinki Heart Study . Circulation. 92:1995;1779-1785.
78. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 338:1998;867-872.
79. Mancini C.B.J., Henry G.C., Macay C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease The TREND Study (Trial on Reversing Endothelial Dysfunction) . Circulation. 94:1996;258-265.
80. Jonas M., Reicher-Reiss H., Boyko V., et al. (Bezafibrate Infarction Prevention Study Group BIP) Usefulness of beta-blocker therapy in patients with noninsulin-dependent diabetes mellitus and coronary artery disease . Am J Cardiol. 77:1996;781-786.
81. O'Keefe J.H. Jr, Conn R.D., Lavie C.J. Jr, et al. The new paradigm for coronary artery disease altering risk factors, atherosclerotic plaques, and clinical prognosis . Mayo Clin Proc. 71:1996;957-965.
82. Collaborative overview of randomized trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients . BMJ. 308:1994;81-106.